SCHEMBL10102269

SCHEMBL10102269

COc1ccc(C2(c3ccc(N4CCCCC4)cc3)C=Cc3c(C)cc4cc(C)c(OC)cc4c3O2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.36
KDM4E B2RXH2 4/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
RECQL P46063 1/20 0.36
L3MBTL1 Q9Y468 3/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPK1 P28482 3/20 0.34
TDP1 Q9NUW8 2/20 0.34
TP53 P04637 2/20 0.34
APP P05067 4/20 0.34
CCNC P24863 1/20 0.34
CDK8 P49336 1/20 0.34
TSHR P16473 1/20 0.33
CASP1 P29466 1/20 0.33
AHR P35869 1/20 0.33
CASP7 P55210 1/20 0.33
HSD17B10 Q99714 1/20 0.33
LMNA P02545 1/20 0.33
ACHE P22303 1/20 0.33
ABL1 P00519 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10106931 0.89 MAPT (0.39) MAPTKDM4ESMN1; SMN2RECQLL3MBTL1
SCHEMBL12659492 0.89 MAPT (0.35) MAPTKDM4ESMN1; SMN2RECQLL3MBTL1
SCHEMBL6479818 0.81 MAPT (0.38) MAPTKDM4ESMN1; SMN2RECQLL3MBTL1
SCHEMBL13464678 0.81 HIF1A (0.37) MAPTKDM4ESMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL15277651 0.77 KDM4E (0.32) MAPTKDM4ESMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL7971698 0.77 MAPT (0.38) MAPTKDM4ESMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL7785460 0.76 MAPT (0.39) MAPTSMN1; SMN2L3MBTL1MAPK1TP53
SCHEMBL15458427 0.75 AKT1 (0.32) MAPTKDM4ESMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL7936515 0.75 KEAP1 (0.42) MAPTKDM4EALDH1A1APP
SCHEMBL7722392 0.75 HTR1A (0.37) MAPTKDM4ESMN1; SMN2L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120138876-A1 CHROMENE COMPOUND CHRM1, CBX8, CBX7 MAPT 3134/4885KDM4E 1435/4885SMN1; SMN2 1096/4885
US-20110062396-A1 CHROMENE COMPOUND CDYL, NR0B1, NR1H2 MAPT 4740/4885KDM4E 2629/4885SMN1; SMN2 2922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.